BACKGROUND
This combination of features is known by many designations, including atherogenic dyslipidaemia, dyslipidaemia of insulin resistance or the atherogenic lipoprotein phenotype. It contributes to the 2 to 4 times excess risk for cardiovascular disease observed in patients with type 2 diabetes mellitus compared with nondiabetic individuals [6] . It is also increasingly recognized that the presence of diabetes places most patients at the same near-term risk for a coronary event as that of a patient with existing coronary heart disease (CHD). Diabetes incidence is increasing rapidly in the general population, drawing attention to the role of atherogenic dyslipidaemia in the evolution of CHD among these patients. Attempts to correlate CHD incidence among patients with diabetes with the classic coronary risk factors, showed that these risk factors account for only 25% to 30% of the excess risk for CHD [7] . The degree to which hyperglycemia makes up the difference in risk observed in the diabetic compared with the nondiabetic population is unresolved. Aggressive glycemic control substantially reduces the incidence of microvascular complications of diabetes, such as retinopathy and nephropathy, however the benefits in terms of macrovascular complications, including CHD, have been more difficult to document. Lowering LDL-C levels with 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors significantly reduces the risk for major coronary events in patients with diabetes [8] .
The discovery of metformin began with the synthesis of galegine-like compounds derived from Gallega officinalis, a plant traditionally employed in Europe as a drug for diabetes treatment for centuries [9] . Metformin acts primarily at the liver by reducing glucose output and secondarily, by augmenting glucose uptake in the peripheral tissues, chiefly muscle. These effects are mediated by the activation of an upstream kinase, liver kinase B1 (LKB-1), which in turn regulates the downstream kinase adenosine monophosphatase protein kinase (AMPK). AMPK phosphorylates a transcriptional co-activator, transducer of regulated CREB protein 2 (TORC2), resulting in its inactivation which consequently downregulates transcriptional events that promote synthesis of gluconeogDyslipidemia is one of the major cardiovascular disease risk factors and plays an important role in the progress of atherosclerosis, the underlying pathology of CVD. The prevalence of dyslipidemia in type 2 diabetes is double with respect to the general population. These are more complex abnormalities that are caused by the interrelation among obesity and insulin resistance [1] . The characteristic features of diabetic dyslipidaemia are a high plasma triglyceride concentration, low HDL cholesterol concentration and increased concentration of small dense LDL-cholesterol particles. The lipid changes associated with diabetes mellitus are attributed to increased free fatty acid flux secondary to insulin resistance. The availability of multiple lipid-lowering drugs and supplements provides new opportunities for patients to achieve target lipid levels [2] . Patients with diabetes mellitus are at higher risk for cardiovascular events than those without diabetes. Furthermore, patients with diabetes have a characteristic 'lipid triad' of low high-density lipoprotein-cholesterol levels, high triglyceride levels and normal or slightly raised low-density lipoprotein-cholesterol levels, with a preponderance of small, dense LDL-C particles. Current guidelines on preventing cardiovascular disease recognize the need not only to reduce LDL-C levels, but also to increase HDL-C and decrease triglyceride levels in diabetic patients [3] .
Alterations in lipid metabolism are recognized concomitant symptoms of diabetes mellitus. It is believed that even before the development of overt diabetes, insulin resistance and a prediabetic state impair the mechanism that suppresses fatty acid release from adipose tissue after food intake [4] . The resultant excess of free fatty acids leads to increased concentrations of triglyceride (TG)-rich particles (very low-density lipoproteins and chylomicrons) and TG enrichment of high-and low-density lipoprotein (HDL and LDL), affecting virtually every lipid and lipoprotein variable [5] . The end result is a dyslipidaemia that is characterized by elevated TG levels, the generation of small, dense LDL particles, and reduced HDL cholesterol (HDL-C) concentrations.
enic enzymes [10] . Inhibition of mitochondrial respiration has also been proposed to contribute to the reduction of gluconeogenesis since it reduces the energy supply required for this process [11] . Metformin's efficacy, security profile, benefic cardiovascular and metabolic effects, and its capacity to be associated with other antidiabetic agents makes this drug the first glucose lowering agent of choice when treating patients with type 2 diabetes mellitus (TDM2). Developing countries are expected to shoulder the majority of the burden of diabetes [12] . One of the main contributing factors to this burden is the Western lifestyle which promotes obesity and sedentarism [13] . Impaired glucose tolerance and impaired fasting glucose statuses are associated with increased and varying risk of developing type 2 diabetes mellitus. Impaired glucose tolerance has been associated with an increased risk of cardiovascular events and may determine an increased mortality risk. The association of impaired fasting glucose with cardiovascular events, however, has not been well established [14] . When lifestyle interventions fail or are not feasible, pharmac-ological therapy may be an important resource to prevent type 2 diabetes. Several different drug classes have been studied for this purpose [15] . The present study is concentrated on effect of metformin on lipid profile of type II diabetes.
MATERIALS AND METHODS
200 subjects were selected from diabetic type II patients who are on treatment of only metformin(1500mg/daily). The parameters were performed after 3 months of treatment. FBS, TC, TGs, HDL-C, LDL-C and VLDL -C were measured. Initially the patients were selected without any treatment and found diabetes, later we have started treated them with metformin(1500mg/ daily). After three months of their treatment we have measured all above mentioned parameters and compared with initial values. The ANOVA performed with posthoc t -test. The values expressed with mean and SD.
there was significance difference after treatment with metformin, the results showed corrected dyslipidaemia after 45 days and after 90 days it has come to almost near to normal. In results observed that decrease in fasting blood glucose, total cholesterol, LDL-C and TGs. HDL-C levels were increased significantly after treatment (Table -1) .
RESULTS
The fasting blood samples were collected 0 day of treatment, 45 th day of treatment and 90 th day of treatment. The results were clearly indicated 
Groups

DISCUSSION
The present study showed the beneficial effect clearly after the 45 th day of treatment and 90 days of treatment. It is showed clearly metformin treatment is clearly indicating that after the treatment diabetic patient corrected the dyslipidaemia. A meta-analysis of 41 randomized, controlled evaluations ofmetformin of at least 6-week duration showed significant reductions in total cholesterol, LDL cholesterol and triglycerides in patients randomized to metformin relative to comparator treatments [16] , HDL-cholesterol was rarely improved by metformin treatment. Some nonrandomized studies have demonstrated significant reductions in free fatty acids following treatment with metformin [17] . In nondiabetic persons and those with impaired glucose tolerance randomized in the Diabetes Prevention Program [18] , the metformin effect on lipid profile was modest and generally smaller than the effect of the intensive lifestyle intervention included in this trial. It suggests that reductions in the risk of macrovascular endpoints with metformin, showed in the UK Prospective Diabetes Study [19] , is associated with other mechanisms, not only the effects on lipids. Metformin also decreases oxidative stress, inhibits lipid peroxidation of LDL and HDL, and the production of the superoxide free radical in platelets [20] . Metformin may reduce the production of advanced glycation endproducts indirectly, by reduction of hyperglycemia, and directly by an insulininde pendent mechanism [21] . Experimental studies Suggest that metformin may inhibit the binding of monocytes to cultured vascular cells and differentiation of monocytes into macrophages and their transformation into foam cells [22] .
In consistent with many studies, significant improvement in glycemic parameters (FBG) was seen over a short period of 8-12 weeks in moderately severe, newly diagnosed diabetic patients treated with either glimepiride, metformin or combination, when compared with pre-treatment [23, 24, 25] . The improvements in glycaemic parameters with glimepiride and metformin were similar, while combination produced a lower degree of reduction with respect to the change in FBG [26, 27, 28] . The previous studies approved that glimepiride increases insulin sensitivity at peripheral target sites and improve glycemic control in newly diagnosed diabetic subjects, The extrapancreatic effects of glimepiride made its combination with metformin more effective in improving glycemic control by reducing glucose level [29, 30] . Newly diagnosed type 2 diabetic patients, at baseline, show varying features with respect to lipid profile, present study agreed with previous studies; demonstrated that metformin as monotherapy reduced TC, LDL-C, significant decrease in TG levels [31, 32, 33] and increase serum HDL-C level. Therefore, our results concluded that metformin used in diabetic treatment improves lipid profile in agreement with previous studies.
